Targeting inflammation: Implications for chronic disease and cancer therapy

Sina  Salem Ahim; Mohammad  Kaveh

doi:10.61882/jcbior.6.4.344

Authors

Sina Salem Ahim School of Medicine, Fasa University of Medical Sciences, Fasa, Iran https://orcid.org/0009-0008-2452-434X
Mohammad Kaveh Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran https://orcid.org/0009-0002-9829-8708

DOI:

https://doi.org/10.61882/jcbior.6.4.344

Keywords:

Inflammation, Immunology, Cancer, Immune signaling

Abstract

No abstract.

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-84. DOI: 10.1038/ni.1863 PMID: 20404851

[2] Ablasser A, Chen ZJ. cGAS in action: Expanding roles in immunity and inflammation. Science. 2019;363(6431):eaat8657. DOI: 10.1126/science.aat8657 PMID: 30846571

[3] Wang Z, Zhang S, Xiao Y, Zhang W, Wu S, Qin T, et al. NLRP3 Inflammasome and Inflammatory Diseases. Oxid Med Cell Longev. 2020;2020:4063562.

DOI: 10.1155/2020/4063562 PMID: 32148650

[4] Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668-77.

DOI: 10.1016/j.autrev.2013.12.004 PMID: 24418308

[5] Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538-42.

DOI: 10.1016/j.autrev.2009.01.012 PMID: 19189867

[6] Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020;76(14):1660-1670.

DOI: 10.1016/j.jacc.2020.08.011 PMID: 33004131

[7] Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, et al. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018;71(21):2405-2414.

DOI: 10.1016/j.jacc.2018.03.490 PMID: 29793629

[8] Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med. 2018;33(1):20-27.

DOI: 10.3904/kjim.2017.393 PMID: 29223139

[9] Li J, Zou Y, Kantapan J, Su H, Wang L, Dechsupa N. TGF β/Smad signaling in chronic kidney disease: Exploring post translational regulatory perspectives (Review). Mol Med Rep. 2024;30(2):143.

DOI: 10.3892/mmr.2024.13267 PMID: 38904198

[10] Tan Y, Wang M, Zhang Y, Ge S, Zhong F, Xia G, Sun C. Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. Front Oncol. 2021;11:693517.

DOI: 10.3389/fonc.2021.693517 PMID: 34178692

[11] Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41. DOI: 10.1016/j.immuni.2019.06.025 PMID: 31315034

[12] Chen H, Yang H, Guo L, Sun Q. The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances. MedComm (2020). 2025;6(10):e70412.

DOI: 10.1002/mco2.70412 PMID: 41059489

[13] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. DOI: 10.1056/NEJMoa1200690 PMID: 22658127

[14] Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.

DOI: 10.3389/fimmu.2023.1188049 PMID: 37256141

[15] Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer. 2023;11(11):e007530.

DOI: 10.1136/jitc-2023-007530 PMID: 37945321

[16] Nishida A, Andoh A. The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis. Cells. 2025;14(7):488.

DOI: 10.3390/cells14070488 PMID: 40214442

[17] Liu D, Jenkins RW, Sullivan RJ. Mechanisms of Resistance to Immune Checkpoint Blockade. Am J Clin Dermatol. 2019;20(1):41-54.

DOI: 10.1007/s40257-018-0389-y PMID: 30259383